Evolution entre 2007 et 2009 de la résistance de Pseudomonas aeruginosa à la ciprofloxacine en fonction de la consommation des fluoroquinolones au CHU d'Angers

National audienc

Réservoir extra-digestif d’entérobactéries productrices de bêtalactamase à spectre élargi chez des patients non infectés: étude à partir d’une recherche systématique dans les urines et d’autres prélèvements à visée diagnostique

Notre objectif était d’étudier le réservoir extra-digestif d’entérobactéries productrices de β-lactamases à spectre élargi (EBLSE) en les recherchant dans des prélèvements à visée diagnostique (PVD) pour lesquels les colonies bactériennes isolées sur les milieux de cultures utilisés ne sont pas obligatoirement analysées (identification bactérienne et antibiogramme) en routine. Pendant une période de 5 semaines, des identifications et des antibiogrammes ont été réalisés de manière systématique pour les colonies correspondant à des entérobactéries isolées dans certains PVD comme les urines, les prélèvements respiratoires, et un groupe de prélèvements appelé “divers”. Les prélèvements pour lesquels un antibiogramme a été réalisé conformément à la pratique de routine du laboratoire ont été considérés comme infectés. Les prélèvements pour lesquels les entérobactéries ont été recherchées et étudiées suivant le protocole de l’étude ont été considérés comme colonisés. Au cours de l’étude, 2 312 urines, 327 prélèvements respiratoires et 1 887 prélèvements divers ont été envoyés au laboratoire. Parmi les 114 urines colonisées par au moins une entérobactérie, 13 (11,4 %) comportaient une EBLSE, alors que cette proportion était de 5,1 % (35/682) dans les urines infectées (p < 0,01). Parmi les prélèvements respiratoires et divers, 3 EBLSE ont été isolées dans 55 prélèvements colonisés par au moins une entérobactérie. Au total, la recherche systématique d’EBLSE dans les PVD a permis une augmentation de 27,7 % du nombre de patients identifiés comme porteurs de ces bactéries. D’autres études pourraient être utiles pour évaluer l’intérêt de mettre en place une telle stratégie comme alternative au dépistage rectal habituellement pratiqué

Direct comparison of phase-space distributions of K- and K+ mesons in heavy-ion collisions at SIS energies - evidence for in-medium modifications of kaons ?

The ratio of K- to K+ meson yields has been measured in the systems RuRu at 1.69 A GeV, Ru+Zr at 1.69 A GeV, and Ni+Ni at 1.93 A GeV incident beam kinetic energy. The yield ratio is observed to vary across the measured phase space. Relativistic transport-model calculations indicate that the data are best understood if in-medium modifications of the kaons are taken into account.Comment: 14 pages including 3 figure

BAs and boride III-V alloys

Boron arsenide, the typically-ignored member of the III-V arsenide series BAs-AlAs-GaAs-InAs is found to resemble silicon electronically: its Gamma conduction band minimum is p-like (Gamma_15), not s-like (Gamma_1c), it has an X_1c-like indirect band gap, and its bond charge is distributed almost equally on the two atoms in the unit cell, exhibiting nearly perfect covalency. The reasons for these are tracked down to the anomalously low atomic p orbital energy in the boron and to the unusually strong s-s repulsion in BAs relative to most other III-V compounds. We find unexpected valence band offsets of BAs with respect to GaAs and AlAs. The valence band maximum (VBM) of BAs is significantly higher than that of AlAs, despite the much smaller bond length of BAs, and the VBM of GaAs is only slightly higher than in BAs. These effects result from the unusually strong mixing of the cation and anion states at the VBM. For the BAs-GaAs alloys, we find (i) a relatively small (~3.5 eV) and composition-independent band gap bowing. This means that while addition of small amounts of nitrogen to GaAs lowers the gap, addition of small amounts of boron to GaAs raises the gap (ii) boron ``semi-localized'' states in the conduction band (similar to those in GaN-GaAs alloys), and (iii) bulk mixing enthalpies which are smaller than in GaN-GaAs alloys. The unique features of boride III-V alloys offer new opportunities in band gap engineering.Comment: 18 pages, 14 figures, 6 tables, 61 references. Accepted for publication in Phys. Rev. B. Scheduled to appear Oct. 15 200

Sideward flow of K+ mesons in Ru+Ru and Ni+Ni reactions near threshold

Experimental data on K+ meson and proton sideward flow measured with the FOPI detector at SIS/GSI in the reactions Ru+Ru at 1.69 AGeV and Ni+Ni at 1.93 AGeV are presented. The K+ sideward flow is found to be anti-correlated (correlated) with the one of protons at low (high) transverse momenta. When compared to the predictions of a transport model, the data favour the existence of an in-medium repulsive K+ nucleon potential.Comment: 16 pages Revtex, 3 ps-figures, submitted to Phys. Lett.

The HERMES Spectrometer

The HERMES experiment is collecting data on inclusive and semi-inclusive deep inelastic scattering of polarised positrons from polarised targets of Il, D, and He-3. These data give information on the spin structure of the nucleon. This paper describes the forward angle spectrometer built for this purpose. The spectrometer includes numerous tracking chambers (micro-strip gas chambers, drift and proportional chambers) in front of and behind a 1.3 T.m magnetic field, as well as an extensive set of detectors for particle identification (a lead-glass calorimeter, a pre-shower detector, a transition radiation detector, and a threshold Cherenkov detector). Two of the main features of the spectrometer are its good acceptance and identification of both positrons and hadrons, in particular pions. These characteristics, together with the purity of the targets, are allowing HERMES to make unique contributions to the understanding of how the spins of the quarks contribute to the spin of the nucleon. (C) 1998 Elsevier Science B.V. All rights reserved

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362